Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Oval lenses may finally solve scleral lens discomfort

NCT ID NCT07288658

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether scleral lenses with an oval-shaped limbal zone fit better and feel more comfortable than traditional round designs. Seven existing scleral lens wearers tried both lens shapes, and researchers used advanced eye imaging to measure how well each lens cleared the limbus. The goal is to improve comfort and eye health for people who rely on scleral lenses daily.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Scleral lenses with oval and circular limbal zone designs
What this could lead to
If oval limbal zones fit better, this could lead to more comfortable and safer scleral lenses for daily wearers.
What could go wrong
This is a very small study (7 people) and only tests one lens brand. Results may not apply to all lens types or users.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

7 people

The number who actually took part.

Started

Jan 2026

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Are at least 18 years of age and has full legal capacity to volunteer; * Have signed an information consent letter; * Are willing and able to follow instructions and maintain the appointment schedule; * Are existing wearers of WAVE ScleraLens in one or both eyes. Exclusion Criteria: * Are participating in any concurrent clinical or research study; * Have any known active\* ocular disease and/or infection; * Have known sensitivity to the diagnostic pharmaceuticals to be used in the study; * Have taken part in another (pharmaceutical) research study within the last 30 days; \* For the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. Mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and mild dry eye are not considered active ocular disease. Neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Limbus corneae are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • School of Optometry & Vision Science, University of Waterloo

    Waterloo, Ontario, N2L 3G1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.